A detailed history of Daiwa Securities Group Inc. transactions in Zai Lab LTD stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 9,557 shares of ZLAB stock, worth $245,614. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,557
Previous 193 4851.81%
Holding current value
$245,614
Previous $3,000 7600.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$16.25 - $24.14 $152,165 - $226,046
9,364 Added 4851.81%
9,557 $231,000
Q3 2023

Nov 01, 2023

SELL
$22.72 - $31.49 $1,931 - $2,676
-85 Reduced 30.58%
193 $5,000
Q4 2022

Feb 06, 2023

BUY
$22.28 - $38.71 $512 - $890
23 Added 9.02%
278 $9,000
Q2 2022

Aug 09, 2022

BUY
$23.14 - $49.68 $1,157 - $2,484
50 Added 24.39%
255 $9,000
Q1 2022

Apr 29, 2022

SELL
$27.77 - $64.4 $50,846 - $117,916
-1,831 Reduced 89.93%
205 $9,000
Q4 2021

Feb 03, 2022

SELL
$54.9 - $105.21 $1,811 - $3,471
-33 Reduced 1.59%
2,036 $128,000
Q3 2021

Nov 05, 2021

BUY
$105.0 - $178.37 $204,855 - $347,999
1,951 Added 1653.39%
2,069 $218,000
Q1 2021

May 03, 2021

BUY
$126.27 - $191.71 $1,641 - $2,492
13 Added 12.38%
118 $16,000
Q4 2020

Feb 04, 2021

SELL
$81.94 - $135.34 $16,388 - $27,068
-200 Reduced 65.57%
105 $14,000
Q3 2020

Nov 02, 2020

BUY
$73.3 - $89.48 $4,031 - $4,921
55 Added 22.0%
305 $25,000
Q1 2020

May 14, 2020

BUY
$39.1 - $62.9 $1,564 - $2,516
40 Added 19.05%
250 $13,000
Q4 2019

Jan 31, 2020

SELL
$29.79 - $43.06 $357 - $516
-12 Reduced 5.41%
210 $9,000
Q3 2019

Nov 04, 2019

BUY
$30.47 - $37.65 $2,742 - $3,388
90 Added 68.18%
222 $7,000
Q1 2019

Apr 26, 2019

SELL
$21.71 - $31.54 $2,561 - $3,721
-118 Reduced 47.2%
132 $4,000
Q4 2018

Feb 05, 2019

BUY
$14.95 - $24.72 $3,737 - $6,180
250 New
250 $6,000

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.52B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.